What is Anokion?
Anokion US, Inc. operates at the intersection of immunology and therapeutic protein engineering. The company specializes in developing antigen-specific immune tolerance technology designed to address the root causes of autoimmune conditions and allergies. Unlike conventional immunosuppressive therapies that often compromise the entire immune system, Anokion's platform offers a highly specific approach, aiming to restore immune balance while maintaining overall patient health. This innovative methodology is particularly significant for reducing the immunogenicity of therapeutic proteins, thereby enhancing the efficacy and safety profiles of existing and future medical interventions. By targeting the underlying mechanisms of disease, Anokion is positioning itself as a critical player in the next generation of precision medicine.
How much funding has Anokion raised?
Anokion has raised a total of $75M across 2 funding rounds:
Series A
$40M
Private Equity
$35M
Series A (2019): $40M, investors not publicly disclosed
Private Equity (2022): $35M led by Pfizer Breakthrough Growth Initiative
Key Investors in Anokion
Pfizer Breakthrough Growth Initiative
A strategic investment arm of a global pharmaceutical leader focused on accelerating the development of innovative therapies through equity financing.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Anokion?
With the recent influx of capital, Anokion is well-positioned to accelerate its clinical pipeline and expand the reach of its platform technology. The strategic focus will likely shift toward scaling manufacturing capabilities and advancing lead candidates through rigorous clinical trials. As the company continues to refine its antigen-specific strategies, it remains a focal point for stakeholders interested in the future of autoimmune disease management. The integration of this financing will be instrumental in navigating the complexities of late-stage development, ensuring that the company can effectively translate its scientific breakthroughs into tangible, market-ready solutions that meet the high standards of modern healthcare.
See full Anokion company page
